Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management

Maria Vittoria Cannizzaro, Chiara Franceschini, Maria Esposito, Luca Bianchi, Alessandro Giunta Department of Dermatology, University of Rome Tor Vergata, Rome, Italy Abstract: The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	HBV reactivation anti-TNF-alpha psoriasis immune-mediated diseases HBV reactivation prevention biologics Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/de6d257625d343eeb35c247a9792c640
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de6d257625d343eeb35c247a9792c640
record_format	dspace
spelling	oai:doaj.org-article:de6d257625d343eeb35c247a9792c6402021-12-02T03:26:49ZHepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management2230-326Xhttps://doaj.org/article/de6d257625d343eeb35c247a9792c6402017-04-01T00:00:00Zhttps://www.dovepress.com/hepatitis-b-reactivation-in-psoriasis-patients-treated-with-anti-tnf-a-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XMaria Vittoria Cannizzaro, Chiara Franceschini, Maria Esposito, Luca Bianchi, Alessandro Giunta Department of Dermatology, University of Rome Tor Vergata, Rome, Italy Abstract: The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α. Although anti-TNFs are considered moderate immunosuppressive drugs, the incidence of HBVr in psoriatic patients is lower compared to patients affected by other immune-mediated diseases treated with TNF inhibitors. HBV prophylaxis should be probably reserved to anti-HBs+/anti-HBc+ patients with a viral load <2000 IU/mL and alterations in serum liver enzymes, in order to prevent HBVr. Keywords: HBV reactivation, anti-TNF-α, psoriasis, immune-mediated diseases, HBV reactivation prevention, biologicsCannizzaro MVFranceschini CEsposito MBianchi LGiunta ADove Medical PressarticleHBV reactivationanti-TNF-alphapsoriasisimmune-mediated diseasesHBV reactivation preventionbiologicsDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 7, Pp 35-40 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	HBV reactivation anti-TNF-alpha psoriasis immune-mediated diseases HBV reactivation prevention biologics Dermatology RL1-803
spellingShingle	HBV reactivation anti-TNF-alpha psoriasis immune-mediated diseases HBV reactivation prevention biologics Dermatology RL1-803 Cannizzaro MV Franceschini C Esposito M Bianchi L Giunta A Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
description	Maria Vittoria Cannizzaro, Chiara Franceschini, Maria Esposito, Luca Bianchi, Alessandro Giunta Department of Dermatology, University of Rome Tor Vergata, Rome, Italy Abstract: The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α. Although anti-TNFs are considered moderate immunosuppressive drugs, the incidence of HBVr in psoriatic patients is lower compared to patients affected by other immune-mediated diseases treated with TNF inhibitors. HBV prophylaxis should be probably reserved to anti-HBs+/anti-HBc+ patients with a viral load <2000 IU/mL and alterations in serum liver enzymes, in order to prevent HBVr. Keywords: HBV reactivation, anti-TNF-α, psoriasis, immune-mediated diseases, HBV reactivation prevention, biologics
format	article
author	Cannizzaro MV Franceschini C Esposito M Bianchi L Giunta A
author_facet	Cannizzaro MV Franceschini C Esposito M Bianchi L Giunta A
author_sort	Cannizzaro MV
title	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
title_short	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
title_full	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
title_fullStr	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
title_full_unstemmed	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
title_sort	hepatitis b reactivation in psoriasis patients treated with anti-tnf agents: prevention and management
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/de6d257625d343eeb35c247a9792c640
work_keys_str_mv	AT cannizzaromv hepatitisbreactivationinpsoriasispatientstreatedwithantitnfagentspreventionandmanagement AT franceschinic hepatitisbreactivationinpsoriasispatientstreatedwithantitnfagentspreventionandmanagement AT espositom hepatitisbreactivationinpsoriasispatientstreatedwithantitnfagentspreventionandmanagement AT bianchil hepatitisbreactivationinpsoriasispatientstreatedwithantitnfagentspreventionandmanagement AT giuntaa hepatitisbreactivationinpsoriasispatientstreatedwithantitnfagentspreventionandmanagement
_version_	1718401763727376384

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management

Ejemplares similares